Volume 6.48 | Dec 11

Cord Blood News 6.48 December 11, 2014
Cord Blood News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
 
TOP STORY
LMP1-Deficient Epstein-Barr Virus Mutant Requires T Cells for Lymphomagenesis
Researchers found that i.p. injection of human cord blood mononuclear cells infected with a latent membrane protein 1 (LMP1)-deficient Epstein-Barr virus into immunodeficient mice induces B cell lymphomas. [J Clin Invest] Full Article
Learn more: StemSpan™ CD34+ Cell Expansion Supplement
 
PUBLICATIONS (Ranked by impact factor of the journal)
Genome-Wide DNA Methylation Analysis in Precursor B-Cells
In order to elucidate the influence of DNA methylation during B-cell development, genome-wide DNA methylation status of pro-B, pre-BI, pre-BII, and naive-B-cells isolated from human umbilical cord blood was determined using the methylated CpG island recovery assay followed by next generation sequencing. [Epigenetics] Abstract

Epigenome-Wide Analysis of Neonatal CD4 T-Cell DNA Methylation Sites Potentially Affected by Maternal Fish Oil Supplementation
To determine whether the biological effects of maternal omega-3 polyunsaturated fatty acids supplementation are mediated through DNA methylation, researchers analyzed CD4+ T-cells purified from cryo-banked cord blood samples from a previously conducted clinical trial. [Epigenetics] Abstract

Human Mesenchymal Stem Cells Possess Different Biological Characteristics but Do Not Change Their Therapeutic Potential when Cultured in Serum Free Medium
Growth, multipotency, surface antigen expression, telomerase, immunosuppressive ability, gene expression profile and genomic stability of human umbilical cord mesenchymal stem cells cultured in serum free medium and serum-containing medium were analyzed and compared side by side. [Stem Cell Res Ther]
Abstract | Full Article

Pre-Treatment of Human Umbilical Cord-Derived Mesenchymal Stem Cells with Interleukin-6 Abolishes Their Growth-Promoting Effect on Gastric Cancer Cells
The authors focused on the phenotype and function of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) pre-treated with interleukin-6 (IL-6) in gastric cancer. They found that the protein levels of α-smooth muscle actin were upregulated, and phosphorylated nuclear factor-κB protein levels were downregulated in the hUCMSCs pre-treated with IL-6, as shown by western blot analysis. [Int J Mol Med]
Abstract | Download Full Article

Bone Marrow Mesenchymal Stem Cells Suppressing Activation of Allogeneic Cytokine-Induced Killer/Natural Killer Cells Either by Direct or Indirect Interaction
Investigators explored the effect of mesenchymal stem cells on the cell cycle, apoptosis rate and the expression of CD69, an activation marker, on the allogeneic cord blood derived cytokine-induced killer/natural killer cells. [Cell Biol Int] Abstract

Growth Factors Mediated Differentiation of Mesenchymal Stem Cells to Cardiac Polymicrotissue Using Hanging Drop and Bioreactor
Investigators created cardiac polymicrotissue from human umbilical cord matrix mesenchymal stem cells using a combination of growth factors (sphingosine-1-phosphate and suramin) and techniques (hanging drop and bioreactor). [Cell Biol Int] Abstract

Phenotypical and Functional Characteristics of Mesenchymal Stem Cells Derived from Equine Umbilical Cord Blood
Investigators optimized methodology for isolation, cultural characterization, differentiation and immunophenotyping of mesenchymal stem cells from equine umbilical cord blood. [Cytotechnology] Abstract

Take the "if" out of "diff": Reduce variability when differentiating to hematopoietic cells
 
REVIEWS
Rabbit ATG in Allogeneic Hematopoietic Cell Transplantation
Prophylaxis using ATG infused with conditioning for adult marrow or blood stem cell transplantation reduces both acute and chronic graft-vs-host disease (GvHD). However, ATG is not or minimally efficacious in steroid refractory GvHD treatment. Regarding preemptive therapy, ATG is promising, however, further work is needed on establishing adequate biomarkers to be used as triggers for preemptive therapy before it can be used routinely. [Biol Blood Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
 
SCIENCE NEWS
Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced from Umbilical Cord Blood
Fate Therapeutics, Inc. presented an overview of the effects of using its nutrient-rich media formulation in the ex vivo programming of CD34+ cells sourced from umbilical cord blood. [Press release from Fate Therapeutics, Inc. discussing research presented at the 56th Annual Meeting of the American Society of Hematology (ASH), San Francisco] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration).
Request your free copy.
 
INDUSTRY NEWS
Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes
Pluristem Therapeutics Inc. announced that it has entered into a long-term collaboration agreement with Hadassah Medical Center in Jerusalem. The medical center’s Department of Bone Marrow Transplantation and Cancer Immunotherapy will use preclinical models to assess the potential efficacy of PLX-RAD cells for treatment and prevention of hematological deficiencies and complications of bone marrow and umbilical cord blood transplantation. [Pluristem Therapeutics Inc.] Press Release

Title21 Health Solutions Announces a New Class of Technology in Cellular Therapy
Title21 Health Solutions™ announced the release of a new class of technology which enables cellular therapy environments, transplant centers and cord blood banks to achieve a paperless, traceable laboratory environment through seamless automation and integration. [Title21 Health Solutions] Press Release

CBR’s President and CEO Named as Founding Member of New Cord Blood Banking Association
Cord Blood Registry® (CBR®) announced that Geoffrey Crouse, the company’s president and chief executive officer, is one of the 13 members of the founding board of The Cord Blood Association, a new trade and professional association organized for cord blood banking. [Cord Blood Registry] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Stem Cells in Drug Discovery
June 2-3, 2015
Cambridge, United Kingdom

Visit our events page to see a complete list of events in the cord blood community.
 
JOB OPPORTUNITIES
NEW Director of Bone Marrow Transplant (University of Utah)

Postdoctoral Positions – Stem Cells and Bioengineering (Queensland University of Technology)

Mesenchymal Stem Cell (MSC) Laboratory Technician (California Cryobank)

Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

PhD Student – Department of Hematopoiesis (Sanquin)

Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School at Houston)

Postdoctoral Fellow – Molecular Mechanisms Regulating Human Hematopoietic Specification (Washington University School of Medicine)

Quality Improvement Coordinator – Regenerative Medicine (The University of Texas Health Science Center at Houston)

Cord Tissue Processing Technician (Cord Blood Registry)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us